Robert K Hastings

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1774430/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Research, 2015, 43, W589-W598.	14.5	682
2	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research, 2019, 25, 4255-4263.	7.0	281
3	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research, 2017, 23, 88-96.	7.0	186
4	GWAS Central: a comprehensive resource for the comparison and interrogation of genome-wide association studies. European Journal of Human Genetics, 2014, 22, 949-952.	2.8	155
5	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Chemistry, 2015, 61, 974-982.	3.2	155
6	Epigenetic Control of Retrotransposon Expression in Human Embryonic Stem Cells. Molecular and Cellular Biology, 2011, 31, 300-316.	2.3	128
7	Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Research, 2019, 21, 149.	5.0	89
8	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. Clinical Chemistry, 2017, 63, 532-541.	3.2	81
9	HGVbaseG2P: a central genetic association database. Nucleic Acids Research, 2009, 37, D797-D802.	14.5	60
10	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget, 2017, 8, 87221-87233.	1.8	38
11			
11	Circulating tumour-derived DNA in metastatic soft tissue sarcoma. Oncotarget, 2018, 9, 10549-10560.	1.8	29
12	Circulating tumour-derived DNA in metastatic soft tissue sarcoma. Oncotarget, 2018, 9, 10549-10560. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776.	1.8 3.0	29 12
	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO		
12	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776. Inclusion of multiple highâ€risk histopathological criteria improves the prediction of adjuvant	3.0	12
12 13	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776. Inclusion of multiple highâ€risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 2021, 78, 838-848. The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients.	3.0 2.9	12 9